{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.6","upperLimit":"34.1","value":"19.1"},{"comment":"The percentage and 95% CI cannot be calculated for this cohort because the participants had no measurable disease.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The percentage and 95% CI cannot be calculated for this cohort because the participants had no measurable disease.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Complete Response (CR) or Partial Response (PR) to Cabozantinib (XL184) assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.","id":"OG000","title":"Cohort 1 - (Urothelial Progressive Disease)"},{"description":"Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.","id":"OG001","title":"Cohort 2 (Bone-only)"},{"description":"Patients with non-transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis.","id":"OG002","title":"Cohort 3 (Rare Histologies)"}],"paramType":"NUMBER","populationDescription":"42/50 were analyzed in cohort 1 because 5 participants withdrew, 2 were taken off study for adverse events and 1 was ineligible. In cohort 2, 5/6 patients were analyzed because 1 withdrew; and in cohort 3, 10/13 patients were analyzed because 1 withdrew and 2 were taken off study due to adverse events.","reportingStatus":"POSTED","timeFrame":"Median follow-up was 61.2 months","title":"Percentage of Participants With Overall Response","type":"PRIMARY","unitOfMeasure":"percentage of participants"}